Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.46 USD | -2.61% |
|
-7.77% | -9.27% |
Capitalization | 3.75B 3.63B 3.43B 3.02B 5.37B 326B 5.99B 40.97B 15.12B 136B 14.07B 13.79B 581B | P/E ratio 2024 * |
30.8x | P/E ratio 2025 * | 23.2x |
---|---|---|---|---|---|
Enterprise value | 3.75B 3.63B 3.43B 3.02B 5.37B 326B 5.99B 40.97B 15.12B 136B 14.07B 13.79B 581B | EV / Sales 2024 * |
8.89x | EV / Sales 2025 * | 7.81x |
Free-Float |
96.15% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: ADMA Biologics, Inc.
Wall Street lager gesloten | 22-12-07 | |
Wall Street koerst af op vlak slot | 22-12-07 | |
Wall Street verder omlaag bij opening | 22-12-07 | |
Futures Wall Street wijzen omlaag | 22-12-07 | |
Chinesischer Investor hat Interesse an Biotest | 17-03-30 |
1 day | -2.61% | ||
1 week | -7.77% | ||
Current month | -3.65% | ||
1 month | -5.64% | ||
3 months | -28.56% | ||
6 months | -5.41% | ||
Current year | -9.27% |







Director | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 48 | 2011-09-30 |
Brad Tade
DFI | Director of Finance/CFO | 52 | 2024-07-23 |
Compliance Officer | 38 | 2017-12-31 |
Manager | Title | Age | Since |
---|---|---|---|
Jerrold Grossman
BRD | Director/Board Member | 77 | 2006-12-31 |
Steven Elms
CHM | Chairman | 61 | 2012-03-29 |
Adam Grossman
BRD | Director/Board Member | 48 | 2006-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +3.31% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-2.61% | -7.77% | +184.98% | +854.60% | 3.75B | ||
-0.26% | -6.31% | -15.97% | +3.13% | 78.34B | ||
-1.45% | +15.70% | +41.96% | +53.45% | 57.55B | ||
+0.50% | +1.85% | +101.43% | +124.10% | 37.18B | ||
-5.44% | -8.36% | -45.51% | -37.71% | 20.31B | ||
-0.13% | +0.94% | +391.54% | +837.89% | 13.87B | ||
+0.22% | +0.63% | +75.76% | +141.19% | 13.55B | ||
+2.77% | -9.27% | +18.05% | +3.42% | 12.84B | ||
+1.51% | +0.69% | -26.71% | -28.20% | 12.11B | ||
-0.68% | -3.50% | +4.70% | -37.09% | 11.45B | ||
Average | -0.55% | -1.76% | +73.02% | +191.48% | 26.1B | |
Weighted average by Cap. | -0.60% | -0.92% | +42.63% | +88.88% |
2024 * | 2025 * | |
---|---|---|
Net sales | 422M 408M 386M 340M 605M 36.72B 675M 4.61B 1.7B 15.26B 1.58B 1.55B 65.39B | 481M 464M 439M 387M 688M 41.76B 767M 5.24B 1.94B 17.35B 1.8B 1.77B 74.37B |
Net income | 122M 118M 112M 98.44M 175M 10.62B 195M 1.33B 492M 4.41B 458M 449M 18.91B | 169M 163M 155M 136M 242M 14.71B 270M 1.85B 682M 6.11B 635M 622M 26.2B |
Net Debt | - | - |
Date | Price | Change | Volume |
---|---|---|---|
25-02-12 | 15.56 $ | -2.02% | 1,024,320 |
25-02-11 | 15.88 $ | -4.68% | 1,777,556 |
25-02-10 | 16.66 $ | -0.30% | 1,548,264 |
25-02-07 | 16.71 $ | -1.24% | 1,743,053 |
25-02-06 | 16.92 $ | +0.30% | 2,017,586 |
Delayed Quote Nasdaq, February 12, 2025 at 01:02 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ADMA Stock